Brand Reference: Elidel
| Metric | Verified Benchmark | Source |
|---|---|---|
| Pimecrolimus 1% Topical Cream RxNorm Concept ID | 284527 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.6800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $214.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $36.90 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $41.00 / mo | 13 Zero-PHI Verified Patient Logs |
33-epi-chloro-derivative of ascomycin with higher skin-barrier affinity and 3-fold lower transcutaneous permeation than tacrolimus, selectively silencing mast-cell histamine degranulation and Th2 cutaneous cytokine cascades on delicate periorbital and facial skin.
Across 13 community cost disclosures for Pimecrolimus 1% Topical Cream (Elidel), cash buyers routing around $214.00 retail markups capture a 83% discount ($36.90/mo benchmark vs $1.6800 NADAC acquisition).
Following administration (1% cream applied thin layer BID to sensitive facial/eyelid zones), Pimecrolimus 1% Topical Cream achieves Consistently < 0.5 ng/mL blood concentration bioavailability and 5–10 days facial eczema/periorificial calm onset, governed by a High stratum corneum partitioning terminal half-life through cyp3a4 if trace systemic entry.
Before initiating Pimecrolimus 1% Topical Cream at 1% cream applied thin layer BID to sensitive facial/eyelid zones, clinical safety checklists rule out active viral molluscum or herpes simplex; netherton syndrome. Logged tolerability patterns center on mild warmth day 1–2 (21% of reports), folliculitis (4% of reports).
Across 13 verified cash-pay logs, Pimecrolimus 1% Topical Cream achieves a 87.60% Worth-It rating with out-of-pocket spend averaging $41.00/mo versus $214.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 1% cream applied thin layer BID to sensitive facial/eyelid zones for Pimecrolimus 1% Topical Cream; monthly out-of-pocket dropped to $32.47 compared with $214.00 retail.
Completed 10 weeks on Pimecrolimus 1% Topical Cream (1% cream applied thin layer BID to sensitive facial/eyelid zones). Zero notable side effects on steady dosing.
Consistent biomarker response on 1% cream applied thin layer BID to sensitive facial/eyelid zones Pimecrolimus 1% Topical Cream sourced via Local Pharmacy ($42.80/mo cash pay without insurance prior authorization).